Clinical/scientific notes

Neurology

Volumn 82, Issue 3, 2014, Pages 279-281

  Ahmad, Rawaha ^a,b   Bourgeois, Sophie ^a,b   Postnov, Andrey ^a   Schmidt, Mark E ^c   Bormans, Guy ^b   Van Laere, Koen ^a,b   Vandenberghe, Wim ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

JNJ 42259152; JNJ 42259152 F 18; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RADIOLIGAND; UNCLASSIFIED DRUG; 2-((4-(1-(2-FLUOROETHYL)-4-(4-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENOXY)METHYL)-3,5-DIMETHYLPYRIDINE; 2 ((4 (1 (2 FLUOROETHYL) 4 (4 PYRIDINYL) 1H PYRAZOL 3 YL)PHENOXY)METHYL) 3,5 DIMETHYLPYRIDINE; DIAGNOSTIC AGENT; PDE10A PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXAMINATION; FEMALE; FUNCTIONAL STATUS; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; MENTAL HEALTH; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STRIATE CORTEX; ANIMAL; CELL FRACTIONATION; CORPUS STRIATUM; DENDRITIC SPINE; METABOLISM; METHODOLOGY; MOUSE; NERVE CELL; PATHOLOGY; PILOT STUDY;

ANIMALS; CORPUS STRIATUM; DENDRITIC SPINES; HUMANS; HUNTINGTON DISEASE; MICE; NEURONS; PHOSPHORIC DIESTER HYDROLASES; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIDINES; SUBCELLULAR FRACTIONS;

EID: 84895727405     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000037     Document Type: Article

References (7)

1. Nishi A, Kuroiwa M, Miller DB, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 2008;28:10460-10471.
2. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010;e13417.
3. Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004;123: 967-981.
4. Leuti A, Laurenti D, Giampa C, et al. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2013;52:104-116.
5. Van Laere K, Ahmad RU, Hudyana H, et al. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A (PDE10A) PET tracer: Kinetic Modeling and test-retest study in human brain. J Nucl Med 2013;54:1285-1293.
6. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: Principle and validation. J Nucl Med 1998;39:904-911.
7. Baillie GS. Compartmentalized signalling: Spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J 2009;276:1790-1799.